DDInter923 DDInter350
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) is treated by {v} (Compound) Chlorambucil
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Levodopa {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Chlorambucil
Infliximab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Zinc gluconate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Melphalan
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
DDB2 {u} (Gene) is upregulated by {v} (Compound) Chlorambucil
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Efalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Ustekinumab
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Melphalan
Melphalan {u} (Compound) resembles {v} (Compound) Chlorambucil
Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Melphalan (Compound) and Melphalan (Compound) resembles Chlorambucil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Chlorambucil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Chlorambucil (Compound)
Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib (Compound) downregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) upregulates DDB2 (Gene) and DDB2 (Gene) is upregulated by Chlorambucil (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)
Infliximab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Chlorambucil (Compound)